Orforglipron
Small-molecule oral GLP-1 — no injection, no peptide supply chain.
- Primary research area
- Weight / diabetes
- FDA status
- Oral GLP-1; Phase 3 (2026)
- Last updated
- Apr 21, 2026
- Reviewed by
- Peptide Examiner editorial team
What it is
Orforglipron (brand name Foundayo, if approved) is an investigational oral small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike every previously-approved GLP-1 drug — which are peptides requiring subcutaneous injection — orforglipron is a non-peptide small molecule taken once daily as an oral tablet. This matters because peptide manufacturing bottlenecks and injection aversion have constrained GLP-1 adoption; a pill-based option could dramatically expand addressable market and sidestep the supply-chain issues that created the 2022-2025 shortages.
Mechanism of action
Orforglipron selectively activates the GLP-1 receptor with similar downstream biology to semaglutide — insulin secretion, glucagon suppression, delayed gastric emptying, central appetite suppression. The key pharmacological innovation is that it achieves this activation without being a peptide, which normally suffers from low oral bioavailability because peptides are broken down by stomach acid and gut proteases. As a small molecule, orforglipron survives oral passage and reaches circulation. This also eliminates cold-chain storage requirements.
Research history
Phase 2 data (NEJM, 2023) showed meaningful dose-dependent weight loss in adults with obesity. Phase 3 ATTAIN-1 (obesity) and ACHIEVE-1 (T2D) trial programs ran through 2024-2025. Positive top-line data from ATTAIN-1 (adults with obesity, ~12-15% weight loss at matched durations) and ATTAIN-MAINTAIN (weight maintenance after initial loss) were reported late 2025. Efficacy is somewhat below injectable semaglutide at head-to-head-equivalent durations but the pill-based convenience advantage is material.
Current trial status
Phase 3 complete or near-complete for obesity and T2D indications. Regulatory filings expected 2025-2026. FDA approval timing dependent on filing and review — possibly late 2026 or 2027. Lilly has signaled commercial launch plans that emphasize the oral administration advantage.
Regulatory status
Investigational. Not FDA approved. Expected regulatory filings 2025-2026 with potential approval late 2026 onward. Full regulatory timeline →
Controversies and open questions
Open questions: (1) Does a small-molecule GLP-1 carry the same cardiovascular benefit shown in SELECT for semaglutide? Cardiovascular outcome trials are running but not yet reported. (2) Tolerability at higher doses — GI side effects scale with dose as with peptide GLP-1s; whether patients tolerate orforglipron's effective dose range as well as they tolerate injected semaglutide is still being characterized in real-world data. (3) Competitive landscape — Pfizer and Roche also have oral GLP-1 candidates (danuglipron, aleniglipron); the oral-GLP-1 category will get crowded fast.
Further reading
Frequently asked
Is orforglipron a peptide?
No — it's a small-molecule GLP-1 receptor agonist. This is the key distinction: unlike semaglutide (including the oral Rybelsus form, which uses an absorption enhancer), orforglipron is a conventional orally-absorbed small molecule, not a peptide with special formulation.
Is it as effective as injectable GLP-1s?
Slightly less. Phase 3 data (ATTAIN-1) shows ~12-15% mean weight loss at matched durations vs tirzepatide's ~20% in SURMOUNT-1. Trade-off is meaningful convenience (oral daily vs weekly injection).
When will it be available?
Eli Lilly has submitted regulatory filings. FDA approval is expected late 2026 or 2027 depending on review timeline. Not yet prescribable.
What's the supply-chain advantage?
Small-molecule manufacturing scales with conventional organic chemistry — not constrained by peptide-synthesis capacity the way semaglutide and tirzepatide have been. An oral GLP-1 doesn't bottleneck the way 2022-2025 peptide shortages did.